Oral BG-12 (Dimethyl Fumarate) Significantly Reduced Multiple Sclerosis (MS) Relapses and Disability Progression in Define Phase 3 Clinical Trial --240 mg of BG-12 Administered Either Twice or Three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback